Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.32−0.07 (-5.06%)
Close on Nov 13, 2026Market cap $1.34MP/E –Yield –
Transcode Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Transcode Therapeutics's enterprise value was -$6.97M on Nov 11, 2026, against $4.91M a year earlier. Over the last 5 years it ranged from -$10.47M to $1.37T, with a median of $3.78B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$6.97M | -343.8% |
| 2025 | Dec 31, 2025 | $2.86M | -99.8% |
| 2024 | Dec 31, 2024 | $1.63B | -97.5% |
| 2023 | Dec 29, 2023 | $65.11B | -79.8% |
| 2022 | Dec 30, 2022 | $322.86B | -73.4% |
| 2021 | Dec 31, 2021 | $1.21T | – |
See a number that looks wrong?